Market access abroad: Three reasons why early planning is critical for HTA countries
When launching a product in Europe, there are many factors to consider during the early planning process. A well-prepared market access strategy helps to avoid delays and can maximize the reach and impact your product has once in-market. Regulatory approval may represent a giant leap forward in a product’s path to commercialization, but in Europe and several other regions, it is far from the last step. In these markets, health technology assessments (HTAs) add complexity and nuance to global launch plans. HTAs mandate formal documentation, robust evidentiary requirements, and other activities that convey a therapy’s value. If every obligation is not met, it can delay market entry.
Download the article today to learn why early planning is critical for HTA countries, and gain insight on ways you can be more prepared ahead of your next product launch.
By selecting the “yes” option when filling out the above form, you agree to have your contact information passed along for the purpose of following up on your interests and in order to receive communications regarding Illumina products, services, and events. The data sent will be processed in Canada and provided to Illumina who will assume responsibility for processing and opt-out and information removal. Once your information has been processed by Illumina, communication preferences and opt-out can be managed directly on the Illumina website. For more information, please refer to the Illumina privacy policy.